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Abstract
Introduction: In Kenya, which ranks thirteenth of 27 high tuberculosis burden countries, diagnosis is based on Ziehl-Neelsen staining alone
and patients are treated without information on sensitivity patterns. This study aimed to determine resistance patterns of Mycobacterium
tuberculosis isolated from pulmonary samples.
Methodology: Pulmonary tuberculosis patients in Nairobi were randomly sampled after informed consent and recruited into the study using a
structured questionnaire. Specimens were cultured in liquid and solid media, and drug susceptibility tests were performed for first-line drugs
including (isoniazid, rifampin, streptomycin, ethambutol and pyrazinamide).
Results: Eighty-six (30%) of 286 isolates were resistant to at least one of five antibiotics tested. Thirty-seven (30.2%) isolates were resistant
to isoniazid; 15 (11.6%) to streptomycin; 13 (4.5%) to ethambutol; four (1.4%) to rifampin ; and 30 (10.4%) to pyrazinamide. Double
resistance was seen as follows: four (1.4%) isolates were resistant to both isoniazid and pyrazinamide; four (1.4%) to streptomycin and
isoniazid; and one (0.3%) to rifampin and streptomycin. Two isolates (0.7%) were multidrug resistant, and one was triple resistant with an
additional resistance to ethambutol. Results also showed 88.7% of patients were below the age of 40 years, while 26.3% were HIV positive.
The majority of the patients (66.5%) were unemployed or self-employed in small businesses, with 79.4% earning less than 100 USD per
month.
Conclusion: The high resistance observed in isoniazid, which is a first-line drug, could result in an increase in multidrug resistance unless
control programs are strengthened. Poverty should be addressed to reduce infection rates.
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Introduction
Tuberculosis (TB) has been reported to be
responsible for 1.7 million deaths annually [1];
however, tuberculosis programs face tremendous
challenges
in
reducing
multidrug-resistant
tuberculosis (MDR-TB). Since 1994, only 59% of all
countries globally have been able to collect highquality representative data on drug resistance [1].
Kenya is ranked thirteenth among the 27 high-burden
TB countries in the world and has the fifth highest
burden in Africa [1]. The Kenya National Division of
Leprosy, TB and Lung disease (DLTLD) began to
implement World Health Organization (WHO) direct
observation therapy (DOT) for tuberculosis in 1993
and reported100% coverage by 1996. In 2005 the
DOT case detection rate reached the WHO target of
70% and rose to 72% in 2007 using the Becton and

Dickson BACTEC MGIT 960 (Loveton Circle,
Sparks, USA) technique on the first-line drugs used
for treatment of TB [2]. The DOT treatment success
rate met WHO’s target of 85% in 2007. However,
the WHO Global TB report for 2009 [3] estimated
that Kenya had approximately 132,000 new TB cases
and an estimated 74,000 people died. There are 2,000
treatment facilities and 900 TB diagnosis facilities
throughout the country but they do not cater to drugresistant TB because laboratory diagnosis is mainly
based on Ziehl-Neelsen staining (ZN) without culture
and sensitivity tests. MDR-TB, which is defined as
TB resistant to at least both isoniazid and rifampin,
has been reported since the 1980s in Kenya [4].
According to USAID, it is estimated that there may
have been as many as 2,000 MDR-TB cases in Kenya
in 2007, although only 4.1% of these individuals
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Table 1. Summary of the clinics sampled and patient population
Hospital
Constituency
Population
No. of filter
clinics

TB patient
population (2010)

No. of patients
sampled

Kangemi

Westlands

247,102

10

70

35

Riruta
Mbagathi
Kiambu
Nazareth

Dagoretti
Langata
Kiambaa
Githunguri

329,577
355,188
253,751
147,763

6
20
12
10

130
1390
125
28

77
118
99
27

were diagnosed and notified [5]. MDR-TB patients
are either not receiving treatment or have been
allowed out of hospital because the government does
not have money to treat them. Of the 300 patients
diagnosed with MDR-TB in 2009, only 44 were
receiving treatment while the remaining 256 were not
in any structured treatment [3]. According to the
WHO, an MDR patient infects 10-15 people every
year [5]. Treatment for MDR-TB lasts for 18 months
but can extend to two years or more because it is
difficult to cure and drugs used for treatment are less
potent, more toxic and 50-200 times more expensive
than first-line drugs. If not properly treated it can
result in complications that may require surgical
interventions increasing period of hospitalization and
raising the cost of treatment even higher.
The WHO estimates that globally 4.5 million
people are co-infected with HIV and TB [6]. In
Kenya, about 20% of the 1.2 million HIV-positive
individuals also have TB. Studies show that TB
patients co-infected with HIV are at a higher risk of
having MDR-TB compared to patients without HIV
infection [1]. Little information is available in Kenya
on the resistance patterns of M. tuberculosis;
therefore, this study was undertaken to determine M.
tuberculosis resistance patterns against the first-line
drugs used for treatment in patients diagnosed with
pulmonary tuberculosis.
Methodology
Selection of patient population
A total of five hospitals and TB clinics from
various locations in and around Nairobi, Kenya, were
randomly sampled. These included the Kangemi,
Riruta, and Mbagathi TB clinics as well as Kiambu
District Hospital and Nazareth Hospital (Table 1).
The study was conducted between April and
December 2010 when 356 pulmonary adult TB
patients (18 years of age and older), who consented to
enroll, were systematically sampled on the basis of

being newly clinically diagnosed cases. Out of these
286 173 males (60.3%) and 113 (39.7%) females
were sputum culture positive.
Methodology
Two early morning sputa and a spot sample were
collected in sterile screw-capped bottles. They were
decontaminated with NaOH solution (40g/l4% w/v)
combined with 2.9% sodium citrate solution and Nacetyl-L-cystein (NALC) powder. Sterile phosphate
buffer was added and the organisms concentrated by
centrifugation at 3,000 rpm for 15 minutes. The
supernatant was decanted and the sediment
suspended with phosphate buffer and inoculated in
liquid MGIT media and incubated in BACTEC 960
system (BD Diagnostic Systems, , Sparks, MD, USA)
for a maximum of eight weeks until the culture
flagged positive. The residue was also inoculated in
Lowenstein Jensen (LJ) solid medium and incubated
at 37o C for a maximum of 12 weeks. The growth of
M. tuberculosis thus obtained was used for sensitivity
testing. Statistical analysis was performed by
multiple logistic regression using SPSS version 17
(IBM, Chicago, USA).
Sensitivity testing of M. tuberculosis
All positive tubes were tested for contamination
before sensitivity tests using the standard method
used in Kenya for drug sensitivity testing using the
BACTEC MIGIT 960 liquid culture system (BectonDickson and Company, Sparks, MD, USA).
A total of five first-line drugs collectively
referred to as SIRE (streptomycin [S] - 1.00µg/ml;
isoniazid [INH] - 0.10 µg/ml; rifampin [Rif] - 1.00
µg/ml; and ethambutol [E], 5.00 µg/ml) were tested
for sensitivity along with pyrazinamide (PZA, 100.0
µg/ml). A control tube was matched with all the
isolates tested. An external control of Rv 37 was also
set in all culturing and sensitivity testing processes.

34
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Table 2. Drug resistance patterns of Mycobacterium tuberculosis isolates from pulmonary tubercular
patients in Nairobi
Drug resistance

Patients N

Resistance to any one drug

86 (30.1%)

Mono resistance
Isoniazid
Ethambutol
Streptomycin
Pyrazinamide

26
12
10
26

(12.9%)
(4.5%)
(5.2%)
(12.9%)

Double resistance
Isoniazid and rifampin
Isoniazid and pyrazinamide
Streptomycin and isoniazid
Rifampin and streptomycin

2
4
4
1

(1.1%)
(4.6%)
(4.6%)
(1.2%)

Triple resistance
Isoniazid, rifampin, ethambutol

1 (1.2%)

Each patient was required to complete a structured
questionnaire upon giving informed consent.
Ethical approval
The research proposal was approved and
ethically cleared by the national ethical research
committee (ERC) at the Kenya Medical Research
Institute (KEMRI). Permission was also obtained
from Health Department of Nairobi city council to
sample city council clinics and from the Medical
Officer of Health (MOH) at the Kiambu District
Hospital. Each patient who consented to enroll was
required to complete an informed consent form.
Results
A total of 286 sensitivity tests were performed
from pulmonary tuberculosis patients of whom 173
(60.4 %) were male while 113 (39.5%) were female.
The majority of the patients (88.7%) were below the
age of 40 years while the rest (11.2%) were above the
age of 40 years with only three patients (1%) above
the age of 60 years. Among the pulmonary
tuberculosis patients 26.3% were HIV positive. The
majority of the patients were either unemployed or
self-employed in small businesses (66.5%) with only
33.5% being in formal employment. The number of
participants who were smokers or who consumed
alcohol was also surveyed, and 29.7% of the patients
were found to be smokers and 40% were alcohol
consumers.
A total of 86 (30.1%) strains showed resistance to
at least one drug tested, while 200 (69.9%) were
susceptible. Fifty-two (18.2%) males and 34 (11.9 %)
females showed resistance to at least one drug. The

(%)

isolates showed different resistance patterns with
monoresistance (resistance to at least one drug) in 70
(24.4%) isolates, double resistance in 11 (3.8%)
isolates, and triple resistance in on (0.3%) isolate.
Monoresistance was recorded in all five drugs tested
(Table 2). Isolates were resistant to the antibiotics
tested as follows: 15 (5.2%) were resistant to S; 30
(10.4 %) were resistant to PZA; 37 (12.9%) were
resistant to INH; 13 (4.5%) were resistant to E; and
four (1.4%) were resistant to Rif. Eleven (3.8%)
antibiotics were double drug resistant, two (0.7%) of
which were MDR. Four (1.4%) isolates were resistant
to INH and PZA, 4 (1.4%) to S and INH and 1
(0.3%) to Rif and S. One MDR isolate was triple
resistant with an additional resistance to E.
Discussion
Comparison of resistance on the basis of gender
There was a significantly greater number of
males diagnosed with pulmonary TB than females
(60.4% and 39.5 % respectively; χ2 = 0.963; df = 1; P
< 0.05). This differs with earlier studies in Kenya
where more females were associated with drug
resistance than males (OR = 2.3; 95%Cl 1.2-4.8; P =
0.008) [7]. It compares with studies in Pakistan [8],
however, where drug resistance was associated with
70.9% males and 29.15% females, and also in
Tanzania [9] where drug resistance was associated
with68% males and 32% females. Globally a 70%
predominance of males over female patients was
reported [10]. The World Health Organization
reported that 67.2% of the global male population
was diagnosed with TB as compared to the female
population [6]. The greater number of males
35
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Figure 1. Study profile

compared to females could be attributed to behavioral
factors such as smoking, which is a predisposing
factor to TB with more males being smokers than
females. Alcohol consumption, malnutrition [11] and
the delay in seeking medical treatment, especially by
men [12], are other factors that have been associated
with higher numbers of males than females with TB,

with over 90% of the participants in the current study
being male.
Resistance patterns
The overall resistance to all the drugs tested
(30.1%) was much higher than that reported in earlier
studies in Kenya, where 18.3% of isolates were
resistant to at least one drug [7]. Resistance rates in
36
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the present study were also higher than rates observed
in studies in Tanzania where only 14 out of 280
(5.83%) isolates were resistant to at least one drug
[10], while in Ethiopia resistance rates ranged
from14% to 27.4% [13,14]. In Korea total resistance
was 18.7% [15], while in South Africa total
resistance to the drugs tested was 7.3% [16]. The
results of this study compare with those of studies
conducted in Central Asia where resistance was
30.5% [17]. All these studies were one-time studies
performed in single facilities in the respective
countries. Similarly, in the current investigation was
also a one-time study performed in a single facility.
Resistance to INH in this study was 12.9%,
which was higher than results obtained in earlier
studies in Kenya, where resistance to INH was 10.2%
[18]. INH resistance in the present study was also
much higher than that seen in Ethiopia, where one
isolate was resistant to INH [19], and in Bangladesh
and Sri Lanka at 5.4% [20] and
12.2% [21],
respectively. It was, however, lower than that
reported in Mozambique (14.9%) [22]. In 2008, the
WHO reported a worldwide resistance rate to INH of
5.9% [6]. According to the WHO, INH resistance
rates higher than 10% can predict the development of
MDR TB [23]. This high resistance may be caused by
both its wide use in the treatment of TB as a first-line
drug and/or poor compliance by patients. In this
study, resistance to Rif was 1.3%, which is higher
than that observed in earlier studies in Kenya where
resistance was 0.3 % [18] and in an Ethiopian study
where one isolate was resistant to Rif. This rate is
also higher than reports from studies in Bangladesh
where resistance was 0.5 % [21] and other studies in
Ethiopia where resistance to Rif ranged from 0% to
1.8% [10;15]. Rif has several adverse effects such as
nausea, vomiting, rashes, hepatitis, GIT upset, flulike symptoms, fever and jaundice, which could
result in patient non-adherence and hence may lead to
the selection of resistant strains.
Resistance to S in this study was 5.2%, which
was higher than the resistance of 1.8% [18] reported
in another study in Kenya, but lower than that
reported in Ethiopia (26%) [19] and Sri Lanka 9.9%
[22]. Resistance to E in this study was 4.5% which
was higher than rates in Ethiopia 2.7% [19]. It was,
however, lower than studies conducted in Sri Lanka
where 14.5% resistance was reported [22].
Ethambutol enhances the effect of many drugs
including beta lactams to different Mycobacteria
species and can be used to develop a regimen for
MDR TB [23].
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In this study a high number of patients with TB
showed INH resistance yet susceptibility to all other
tested drugs. According to WHO guidelines for
management of drug-resistant TB, drug-resistant
patients can be classified into three groups: those
releasing bacilli susceptible to all anti-TB drugs;
those releasing bacilli resistant to INH but susceptible
to Rif; and those releasing bacilli resistant to at least
INH and Rif [24]. Most of the isolates in this study
were resistant to INH but susceptible to Rif. It is
therefore possible for these patients to recover fully if
WHO guidelines for retreatment are followed under
strict supervision to prevent them from developing
MDR TB. However, the high rate of INH resistance
is significant since it is a first-line drug which is used
throughout the course of treatment. This indicates a
high probability for developing MDR TB in the
future since it has been observed that MDR often
develops from initial INH monoresistant strains. INH
is also the drug of choice for chemoprophylaxis of
TB and is used in developed countries for treating
latent TB. The high level of INH resistance among
the study population also is an indicator that this drug
will be completely useless for both these purposes in
Kenya.
In this study two patients had MDR-TB (2.3%)
which is not unusual because in sub-Saharan African
countries MDR TB prevalence is estimated to be
6.3% [25].
The results of this study indicate the need for
strict enforcement of the DOTs method and better
epidemiological surveillance of TB cases. Treatment
with internationally approved regimens has resulted
in high cure rates without emergence of resistance
[8]. These regimens are effective in preventing the
emergence of resistance because of inhibition of the
development of spontaneous resistance due to
mutation.
Limitations of the study
This study was conducted over a limited period
of nine months and surveyed only sentinel sites
mostly in high-population density areas of Nairobi
and parts of its environs. Similar studies should be
performed in other regions.
Conclusion
This study serves to inform that MDR may
become an important phenotype in our health
facilities unless TB control programs are
strengthened and continuous systematic surveillance
is adopted. There is urgent need to improve drug
37
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susceptibility testing which is not routinely
performed in public hospitals in Kenya. Furthermore,
there is a need for patients to access rapid diagnosis
and treatment with more effective drugs and also
regimens shorter than the current two-year period for
MDR-TB. Since two cases of XDR-TB have already
been reported in Kenya, there needs to be a
commensurate increase in human resources available
for TB control in both public and private hospitals to
avert a possible explosion of MDR TB. Since drugresistant TB is closely associated with HIV more
research must be conducted to determine if there is an
overlap between MDR-TB and the HIV epidemic.
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